1. Home
  2. EXAS vs CGNX Comparison

EXAS vs CGNX Comparison

Compare EXAS & CGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • CGNX
  • Stock Information
  • Founded
  • EXAS 1995
  • CGNX 1981
  • Country
  • EXAS United States
  • CGNX United States
  • Employees
  • EXAS N/A
  • CGNX N/A
  • Industry
  • EXAS Medical Specialities
  • CGNX Industrial Machinery/Components
  • Sector
  • EXAS Health Care
  • CGNX Industrials
  • Exchange
  • EXAS Nasdaq
  • CGNX Nasdaq
  • Market Cap
  • EXAS 12.3B
  • CGNX 6.9B
  • IPO Year
  • EXAS N/A
  • CGNX 1989
  • Fundamental
  • Price
  • EXAS $71.05
  • CGNX $40.71
  • Analyst Decision
  • EXAS Strong Buy
  • CGNX Buy
  • Analyst Count
  • EXAS 13
  • CGNX 12
  • Target Price
  • EXAS $79.00
  • CGNX $48.58
  • AVG Volume (30 Days)
  • EXAS 1.4M
  • CGNX 1.0M
  • Earning Date
  • EXAS 11-05-2024
  • CGNX 10-30-2024
  • Dividend Yield
  • EXAS N/A
  • CGNX 0.74%
  • EPS Growth
  • EXAS N/A
  • CGNX N/A
  • EPS
  • EXAS N/A
  • CGNX 0.45
  • Revenue
  • EXAS $2,612,011,000.00
  • CGNX $844,000,000.00
  • Revenue This Year
  • EXAS $15.53
  • CGNX $10.64
  • Revenue Next Year
  • EXAS $13.78
  • CGNX $12.99
  • P/E Ratio
  • EXAS N/A
  • CGNX $90.38
  • Revenue Growth
  • EXAS 13.54
  • CGNX N/A
  • 52 Week Low
  • EXAS $40.62
  • CGNX $34.28
  • 52 Week High
  • EXAS $79.62
  • CGNX $53.13
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 55.81
  • CGNX 57.57
  • Support Level
  • EXAS $68.61
  • CGNX $38.42
  • Resistance Level
  • EXAS $71.49
  • CGNX $40.70
  • Average True Range (ATR)
  • EXAS 1.91
  • CGNX 0.88
  • MACD
  • EXAS -0.34
  • CGNX 0.10
  • Stochastic Oscillator
  • EXAS 50.41
  • CGNX 83.27

About EXAS Exact Sciences Corporation

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.

About CGNX Cognex Corporation

Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.

Share on Social Networks: